EE200100621A - MAGi ekspressiooni promootorid - Google Patents

MAGi ekspressiooni promootorid

Info

Publication number
EE200100621A
EE200100621A EEP200100621A EEP200100621A EE200100621A EE 200100621 A EE200100621 A EE 200100621A EE P200100621 A EEP200100621 A EE P200100621A EE P200100621 A EEP200100621 A EE P200100621A EE 200100621 A EE200100621 A EE 200100621A
Authority
EE
Estonia
Prior art keywords
mag expression
compound
formula
present
expression promoter
Prior art date
Application number
EEP200100621A
Other languages
English (en)
Estonian (et)
Inventor
Kawasaki Masakazu
Gotoh Nobuharu
Hayashi Yoshiharu
Kawasaki Kazuyuki
Original Assignee
Mitsubishi Pharma Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Pharma Corporation filed Critical Mitsubishi Pharma Corporation
Publication of EE200100621A publication Critical patent/EE200100621A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EEP200100621A 1999-05-25 2000-05-25 MAGi ekspressiooni promootorid EE200100621A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP14433699 1999-05-25
PCT/JP2000/003373 WO2000071119A1 (fr) 1999-05-25 2000-05-25 Promoteurs de l'expression de la glycoproteine associee a la myeline (mag)

Publications (1)

Publication Number Publication Date
EE200100621A true EE200100621A (et) 2003-02-17

Family

ID=15359751

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100621A EE200100621A (et) 1999-05-25 2000-05-25 MAGi ekspressiooni promootorid

Country Status (21)

Country Link
US (2) US7166630B2 (zh)
EP (1) EP1186296B1 (zh)
KR (1) KR100660955B1 (zh)
CN (1) CN1160072C (zh)
AT (1) ATE359780T1 (zh)
AU (1) AU774471B2 (zh)
BG (1) BG106254A (zh)
BR (1) BR0011551A (zh)
CA (1) CA2373967A1 (zh)
CZ (1) CZ20014203A3 (zh)
DE (1) DE60034448D1 (zh)
EE (1) EE200100621A (zh)
HK (1) HK1044721A1 (zh)
HU (1) HUP0201485A3 (zh)
IL (1) IL146726A0 (zh)
IS (1) IS6173A (zh)
MX (1) MXPA01012188A (zh)
NO (1) NO20015733L (zh)
NZ (1) NZ516261A (zh)
RU (1) RU2241454C2 (zh)
WO (1) WO2000071119A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1354664B1 (de) 2002-04-20 2010-11-17 Haas Laser GmbH & Co. KG Einrichtung zur Überwachung eines optischen Elements eines Bearbeitungskopfes einer Maschine zur thermischen Bearbeitung eines Werkstücks

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19541146A1 (de) 1995-10-25 1997-04-30 Schering Ag Imidazolderivate und deren Verwendung als Stickstoffmonoxid-Synthase-Inhibitoren
CN1092645C (zh) * 1995-12-27 2002-10-16 卫福有限公司 糖尿病并发症的预防/治疗药

Also Published As

Publication number Publication date
NZ516261A (en) 2003-11-28
CN1356900A (zh) 2002-07-03
NO20015733D0 (no) 2001-11-23
IL146726A0 (en) 2002-07-25
US20060270712A1 (en) 2006-11-30
NO20015733L (no) 2002-01-11
EP1186296A4 (en) 2004-12-22
AU774471B2 (en) 2004-07-01
US20050090531A1 (en) 2005-04-28
IS6173A (is) 2001-11-23
EP1186296A1 (en) 2002-03-13
CZ20014203A3 (cs) 2002-06-12
CN1160072C (zh) 2004-08-04
DE60034448D1 (de) 2007-05-31
HUP0201485A3 (en) 2004-01-28
KR100660955B1 (ko) 2006-12-26
EP1186296B1 (en) 2007-04-18
RU2241454C2 (ru) 2004-12-10
ATE359780T1 (de) 2007-05-15
MXPA01012188A (es) 2003-06-30
KR20020015332A (ko) 2002-02-27
HK1044721A1 (zh) 2002-11-01
AU4949700A (en) 2000-12-12
BG106254A (en) 2002-08-30
CA2373967A1 (en) 2000-11-30
WO2000071119A1 (fr) 2000-11-30
BR0011551A (pt) 2002-04-02
US7166630B2 (en) 2007-01-23
HUP0201485A2 (en) 2002-08-28

Similar Documents

Publication Publication Date Title
NO2022019I1 (no) Eribulin eller et farmasøytisk akseptabelt salt derav - forlenget SPC
ID21775A (id) Senyawa-senyawa 1-fenilpirazol dan penggunaan farmasinya
NO953305L (no) Antranilsyrederivat
CY1110322T1 (el) Αναστολεις της her3 δραστικοτητας
DE69012840T2 (de) Adenosin-Derivate, die eine Aktivität gegen Bluthochdruck haben.
PT718293E (pt) Composto ciclodepsipeptidico
ATE183189T1 (de) Antifungale sordaridinderivate
DK132188A (da) Anvendelse af tetrahydrobenz(c,d)indol-6-carboxamider som anxiolytika
ID24846A (id) Turunan-turunan bifenilamidina
NO982873L (no) 1-metylkarbapenemderivater
EE200100621A (et) MAGi ekspressiooni promootorid
NO990672D0 (no) Neuraminsyreforbindelser
ATE360423T1 (de) Verwendung von chymase hemmern gegen vaskuläre lipidablagerung
SE9704770D0 (sv) New use
DE60039782D1 (de) Amidinophenylbrenztraubensäure-derivat
FR2835253B1 (fr) Composes, en particulier de derives urees ou esters de l'acide haloacetamidobenzoique et leur utilisation pour le traitement de maladies parasitaires
EP1210948B8 (en) Therapeutic peptide for nervous diseases